Clinical outcomes after switching from sulfamethoxazole-trimethoprim to atovaquone due to intolerance in patients with non-HIV Pneumocystis pneumonia: a single-center retrospective study
Authors:
Open Access
- 13 January 2026
- journal article
- research article
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 12 (1) , 5
Abstract
Background: Atovaquone (Atov), a second-line drug, is used to treat patients with Pneumocystis pneumonia (PCP) who cannot tolerate sulfamethoxazole/trimethoprim (SMX/TMP). However, the efficacy and safety of Atov are based on clinical trials conducted in patients with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome, with limited data available on HIV-uninfected individuals with PCP (non-HIV PCP). In this study, we retrospectively evaluated the clinical outcomes of switching from SMX/TMP to Atov in patients with non-HIV PCP. Methods: The study included patients with non-HIV PCP who were admitted to Fukuoka University Hospital between 2016 and 2023 and initially received SMX/TMP therapy. The primary endpoint was 30-day survival rate from the date of PCP diagnosis. Secondary endpoints included factors associated with mortality and the cumulative incidence of switching from SMX/TMP to Atov. Results: Of the 56 patients receiving SMX/TMP therapy for PCP, 17 were switched to Atov due to SMX/TMP-related side effects. The Kaplan–Meier estimated 30-day survival was 76.9% in the “remained on” SMX/TMP group and 82.4% in the “switched to” Atov group (log-rank test, P = 0.58). Univariable logistic regression analysis of 30-day mortality showed that switching to Atov was not associated with higher mortality compared with continued SMX/TMP therapy (odds ratio 0.71, 95% confidence interval 0.17 to 3.05). The Kaplan–Meier estimated cumulative incidence of switching from SMX/TMP to Atov during the PCP treatment period was 33.8%. Conclusion: Our data suggest that switching from SMX/TMP to Atov may not be associated with worse survival. Long-term administration of SMX/TMP is often challenging due to its side effects, and in this study, more than 30% of patients were unable to tolerate its therapeutic dose. Our findings support the role of Atov as a viable second-line treatment for PCP in immunocompromised patients, such as those with non-HIV PCP.Keywords
This publication has 25 references indexed in Scilit:
- Fungal infections in HIV/AIDSThe Lancet Infectious Diseases, 2017
- Risk factors for mortality from pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysisOncotarget, 2017
- Pneumocystis jirovecii Pneumonia in the Non–HIV-Infected PopulationAnnals of Pharmacotherapy, 2016
- Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim–sulfamethoxazole: lessons from an observational cohort studyInfection, 2015
- Status of Use and Side Effects of Atovaquone for the Treatment and Prevention of Pneumocystis Pneumonia in HIV Infected Patients in Japan―from 1997 to 2012―The Clinical Study Group for AIDS Drugs, Supported by Health and Labor Science Grants from the Ministry of Health, Labor and Welfare, JapanKansenshogaku Zasshi, 2013
- Pneumocystis cariniiPneumonia in Critically Ill Patients with Malignancy: A Descriptive StudyClinical Infectious Diseases, 2002
- Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk.1995
- Comparison of Atovaquone (566C80) with Trimethoprim-Sulfamethoxazole to Treat Pneumocystis carinii Pneumonia in Patients with AIDSNew England Journal of Medicine, 1993
- A Preliminary Evaluation of 566C80 for the Treatment of Pneumocystis Pneumonia in Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1991
- Safety and Pharmacokinetics of 566C80, a Hydroxynaphthoquinone with Anti-Pneumocystis carinii Activity: A Phase I Study in Human Immunodeficiency Virus (HIV)-Infected MenThe Journal of Infectious Diseases, 1991